Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Firebrick Pharma Limited ( (AU:FRE) ) has provided an announcement.
Firebrick Pharma has reported a sharp fall in half-year revenue to A$63,267 for the period ended 31 December 2025, down nearly 68% from a year earlier, while narrowing its after-tax loss to A$1.26 million, a 12.7% improvement. Net tangible assets per share edged up to 0.77 cents from 0.71 cents, no dividends were declared, and the company’s auditor highlighted a material uncertainty over Firebrick’s ability to continue as a going concern, underscoring ongoing financial pressures despite modest balance sheet gains.
The group reported no acquisitions or disposals of controlled entities, and there were no associate or joint venture interests to affect the results. The financial statements were prepared on a going concern basis, but the auditor’s emphasis of matter signals elevated risk for shareholders and creditors if Firebrick cannot secure sufficient funding or improve operating performance in the medium term.
The most recent analyst rating on (AU:FRE) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Firebrick Pharma Limited stock, see the AU:FRE Stock Forecast page.
More about Firebrick Pharma Limited
Firebrick Pharma Limited is an Australia-based pharmaceutical company listed on the ASX, focused on developing and commercialising health-related products. The company operates in the life sciences sector, targeting consumer and medical markets with its therapies and related technologies.
Average Trading Volume: 104,871
Technical Sentiment Signal: Sell
Current Market Cap: A$15.15M
See more data about FRE stock on TipRanks’ Stock Analysis page.